
    
      To evaluate the efficacy of PTK787/ZK 222584, in inducing at least a 50% reduction in
      paraprotein in patients with multiple myeloma whose paraprotein levels are < 5 g/dL following
      high dose chemotherapy (HDCT) and Autologous Stem Cell Transplantation (ASCT).

      To assess the time to progression and disease free survival of patients treated with
      PTK787/ZK 222584.

      To assess the safety and tolerability of PTK787/ZK 222584 in multiple myeloma patients
      following ASCT.
    
  